Proteinuria or urinary albumin has been considered to be a prognostic marker for patients with non-insulin-dependent diabetes mellitus\(^1\)\(^-\)\(^1\(^4\) and those with hypertension\(^1\(^0\),\(^1\(^5\)-\(^1\(^8\) or acute myocardial infarction.\(^1\(^9\) However, in general population, knowledge about the relationship between proteinuria and mortality is limited.\(^1\(^4\) Proteinuria has been a predictor of mortality in subjects aged 65-79 years\(^2\(^0\) but not among those 80 years and older.\(^2\(^1\) Urinary albumin is related to risk factors for cardiovascular diseases,\(^1\(^5\),\(^2\(^2\) but in only a few studies has diabetes mellitus or the history of renal diseases been assessed.\(^2\(^3\) In addition, most of these studies have been conducted in European countries and in the United States. Studies about the relationship between proteinuria and mortality among non-whites are also limited.\(^8\),\(^1\(^0\) In this study, we describe the relationship between proteinuria at baseline and death from cardiovascular disease in a nationally representative cohort of the Japanese population.

Received August 4, 2004, and accepted April 7, 2005.

This study was supported by the grant-in-aid of the Ministry of Health and Welfare under the auspices of Japanese Association for Cerebro-cardiovascular Disease Control, the Research Grant for Cardiovascular Diseases (7A-2) from the Ministry of Health, Labour and Welfare and a Health and Labour Sciences Research Grant, Japan (Comprehensive Research on Aging and Health: H11-Chouju-046, H14-Chouju-003).

1 Department of Public Health, School of Medicine, Shimane University.
2 Department of Public Health, Jichi Medical School.
3 Department of Hygiene and Preventive Medicine, Iwate Medical University School of Medicine.
4 Department of Preventive Cardiology, National Cardiovascular Center.
5 Department of Health Science, Shiga University of Medical Science.
* Listed in the appendix

Address for correspondence: Shinichi Tanihara, MD, Department of Public Health, School of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan. (e-mail: taniyan@med.shimane-u.ac.jp)

Copyright ©2005 by the Japan Epidemiological Association

---

Proteinuria or urinary albumin has been considered to be a prognostic marker for patients with non-insulin-dependent diabetes mellitus\(^1\)\(^-\)\(^1\(^4\) and those with hypertension\(^1\(^0\),\(^1\(^5\)-\(^1\(^8\) or acute myocardial infarction.\(^1\(^9\) However, in general population, knowledge about the relationship between proteinuria and mortality is limited.\(^1\(^4\) Proteinuria has been a predictor of mortality in subjects aged 65-79 years\(^2\(^0\) but not among those 80 years and older.\(^2\(^1\) Urinary albumin is related to risk factors for cardiovascular diseases,\(^1\(^5\),\(^2\(^2\) but in only a few studies has diabetes mellitus or the history of renal diseases been assessed.\(^2\(^3\) In addition, most of these studies have been conducted in European countries and in the United States. Studies about the relationship between proteinuria and mortality among non-whites are also limited.\(^8\),\(^1\(^0\) In this study, we describe the relationship between proteinuria at baseline and death from cardiovascular disease in a nationally representative cohort of the Japanese population.
Study Subjects

The subjects were the participants of The National Cardiovascular Survey of 1980.24 The procedures of the 1980 National Cardiovascular Survey have already been described.24,25 In 1980, all household members aged 30 years or older living in 300 districts randomly selected throughout Japan were counted. There were 13,771 eligible subjects, among which 10,897 (79.4%) participated in the national survey.

Baseline Information

Using a standard color tone table, the urine dipstick test for protein was carried out and assessed as: none, trace, +, or ++. Blood samples were obtained during a non-fasting state and the time (in hours) between the last meal and the time of sample collection was recorded. Creatinine was measured by using the Jaffe method. Blood sugar was measured by the Neocaproma-copper method. A Technicon SMA 12-60 (Technicon Instruments, Tarrytown, NY) was used for these measurements. Hyperglycemia was defined as a blood sugar level of 7.7 mmol/L or greater when the time from the last meal before blood sampling was two hours or longer and/or 11.1 mmol/L or greater when the elapsed time between the last meal and sampling was less than two hours.

A self-administered questionnaire was used to obtain information on history of gout, hypertension, diabetes mellitus, stroke, heart disease, renal disease, smoking, and alcohol drinking habits. The use of antihypertensive agents was asked to persons with a history of hypertension, although information on specific types of drugs was not obtained. For alcohol drinking habits, the subjects were asked whether they "never drink"; "used to drink"; "occasionally drink"; or "drink daily". For smoking habits, similar questions were posed: whether they "never smoked"; "used to smoke"; or "currently smoke". Both habits were also separated into "current" and "non-current" status. Current drinking included both occasional and daily drinking.

A standard sphygmomanometer was used to measure blood pressure; and the first and the 5th Korotkoff’s sounds were recorded. Creatinine was measured by using the Jaffe method. Blood sugar was measured by the Neocaproma-copper method. A Technicon SMA 12-60 (Technicon Instruments, Tarrytown, NY) was used for these measurements. Hyperglycemia was defined as a blood sugar level of 7.7 mmol/L or greater when the time from the last meal before blood sampling was two hours or longer and/or 11.1 mmol/L or greater when the elapsed time between the last meal and sampling was less than two hours.

Follow-up

In 1994, a follow-up study was conducted with the participants of this survey, which was called the ‘National Integrated Projects for Prospective Observation of Non-Communicable Diseases and the Trend in the Aged’ (NIPPON DATA 80).25,26 A total of 10,546 subjects for whom complete information on age, sex, and blood pressure from the 1980 data set was available made up a cohort. The vital status of these subjects was determined by reviewing the resident registry system of 1994 and 1999. The underlying cause of death of those who died during the follow-up period was obtained from death certificates and coded according to the International Classification of Diseases, 9th revision (ICD9) for the period between 1980 and 1994; and 10th revision (ICD10) for the period between 1995 and 1999. Deaths from stroke (ICD9: 430-438, ICD10: 160-169), cardiovascular diseases (ICD9: 390-459, ICD10: I00-I99), and cancer (ICD9: 140-208, ICD10: C00-C97) were defined as ICD9 or ICD10 codes.

After a follow-up that lasted for 19 years, 908 were lost to follow-up and 759 were excluded because of missing data for potential confounders. For the survival analysis, an additional 1,676 persons with histories of hypertension, stroke, heart disease, renal disease, or diabetes mellitus were excluded because proteinuria or urinary albumin is a predictor of cardiovascular disease mortality for persons with diabetes27 or hypertension.25-28 Finally, 7,203 subjects (3,180 males and 4,023 females) were selected for the study.

Statistical Analysis

Cox’s proportional hazards regression models were used to examine the relationship between proteinuria and cardiovascular mortality. First, proteinuria was considered as a categorical variable and hazard ratios (HR) were calculated for each category (trace, +, ++ and more). Next, proteinuria was diagnosed when a subject showed trace, +, or ++ on the urine dipstick test and considered as a dichotomous variable. The subjects were also divided into three categories according to body mass index (BMI, kg/m2) as follows: “lean” (≤20.0), “standard” (20.1-24.9), and “obese” (≥25); and classified according to serum cholesterol (mmol/L) levels as follows: “low” (<4.1), “standard” (4.1-6.1), and “high” (≥6.2). The serum creatinine level (µmol/L) was rated separately for men and women.27 Male subjects were divided into three categories: “low” (<97), “standard” (97-105), and “high” (≥106). For women, the criteria were set as follows: “low” (<71); “standard” (71-79); and “high” (≥80).27

For comparative purposes, the hazard ratios were calculated with adjustments for age only (grouped by 10-year increments), and with adjustment for age, hypertension (yes/no), hyperglycemia (yes/no), current smoking status (yes/no), current drinking status (yes/no), BMI (lean, standard, or obese), serum cholesterol level (low, standard, or high). To assess the interaction between urinary protein and serum creatinine level, multivariate analyses stratified by the three levels of serum creatinine were conducted. Analyses were performed separately for men and women.

All the analyses was performed with SAS® software (Version 8.2 SAS Institute, Cary, NC). Two-sided values where p < 0.05 were considered statistically significant.

Table 1 shows the number of deaths according to underlying cause of death stratified by baseline proteinuria level. The 19-year
follow-up lasted for 126,825 person-years, during which 1,179 subjects died. Of these, 371 died of cardiovascular causes, including 171 stroke deaths and 71 coronary deaths, and 831 of non-cardiovascular deaths, including 393 who died of cancer and 70 as a result of accidents and injuries. The crude cardiovascular mortality increased with the level of proteinuria for both men and women.

Among the 395 male subjects lost in follow-up, the number of subjects with proteinuria (including trace or more) was 33 (8.4%), as for trace was 16 (4.1%), + was 15 (3.8%), and ++ and more was 2 (0.5%). Among the 513 female subjects lost in follow-up, the number of subjects with proteinuria (including trace or more) was 48 (9.4%), as for trace was 26 (5.1%), + was 20 (3.9%), and ++ and more was 2 (0.4%). Among subjects lost in follow-up, the proportion of subjects with proteinuria was higher than that of subjects completed the follow-up for both men and women.

Table 2 shows the baseline characteristics for subjects with and without proteinuria. For both men and women, the mean age, body mass index, systolic blood pressure, diastolic blood pressure, serum total cholesterol and glucose levels were significantly greater in the subjects with proteinuria. The proportions of subjects with a high serum cholesterol level, obesity, hypertension, or hyperglycemia were significantly greater in the group with proteinuria for both men and women.

Table 3 shows the hazard ratios of proteinuria with all cause and cardiovascular mortality by sex. When examined by using the Cox proportional hazards model adjusted for age only, female subjects with "+" proteinuria significantly associated with all cause mortality. The hazard ratios for male subjects with "++ and more" proteinuria were higher than unity without significance. Proteinuria including trace, +, ++ and more increased the risk with statistical significance with cardiovascular mortality for both men (HR=2.17, 95% CI: 1.39-3.38) and women (HR=2.41, 95% CI: 1.51-3.84).

From the results of multivariate analysis, the hazard ratios of proteinuria with cardiovascular mortality were similar to the models adjusted for age only. The hazard ratios for male subjects with proteinuria including trace, +, ++ and more were higher than unity without significance. The hazard ratios for cardiovascular mortality increased with the level of proteinuria for both men and women when examined by using the Cox proportional hazards model adjusted for age only. Male subjects with "++" proteinuria and female subjects with "+" proteinuria significantly associated with cardiovascular mortality. The hazard ratios for subjects with "trace" proteinuria were higher than unity for both men and women without significance. Proteinuria including trace, +, ++ and more increased the risk with statistical significance with cardiovascular mortality for both men (HR=2.01) and women (HR=2.04, 95% CI: 1.18-3.54). The hazard ratios for male subjects were not statistically significant (HR=1.21, 95% CI: 0.73-2.01).

Table 4 shows the results of stratified analyses by the three levels of serum creatinine. Some of the results from the stratified analysis by serum creatinine level were different from those of age only adjusted models and multivariate analysis. For males, the risk of proteinuria for cardiovascular mortality was significantly higher than unity in the group with standard serum creatinine level. For female subjects, the risk of proteinuria was significantly higher than unity in the group with high creatinine level.

**Table 1.** The number of deaths according to underlying cause stratified by baseline proteinuria level.

| Causes of death          | baseline proteinuria level | Male       | Female     |
|-------------------------|---------------------------|------------|------------|
|                         | total | negative | trace  | +        | ++ and more | total | negative | trace  | +        | ++ and more |
| cardiovascular           | 197   | 175      | 13     | 4        | 5           | 174   | 154      | 9      | 9        | 2           |
| cancer                  | 237   | 224      | 8      | 4        | 1           | 156   | 145      | 7      | 4        | 0           |
| non-cardiovascular, non-cancer | 223   | 203      | 14     | 6        | 0           | 192   | 178      | 10     | 3        | 1           |
| All-cause               | 657   | 602      | 35     | 14       | 6           | 522   | 477      | 26     | 16       | 3           |
| (n=3180)                | (n=2994) | (n=121) | (n=50) | (n=15) |
| (n=4023)                | (n=3804) | (n=150) | (n=57)  | (n=12) |
Table 2. Baseline characteristics of study subjects in 1980 NIPPON DATA, 3180 men and 4203 women aged 30-91 years.

| Characteristics          | Negative (n=2994) | Positive* (n=186) | Negative (n=3804) | Positive* (n=219) |
|--------------------------|-------------------|-------------------|-------------------|-------------------|
| Age (year)               | mean 12.6 SD      | mean 14.0 SD      | mean 12.7 SD      | mean 14.4 SD      |
| Body mass index (kg/m²)  | 22.4 3.0          | 23.2 3.2          | 22.6 3.2          | 23.3 4.1          |
| Systolic blood pressure (mmHg) | 135.4 19.1 | 141.9 22.3 | 130.0 18.7 | 137.8 23.0 |
| Diastolic blood pressure (mmHg) | 82.3 11.5 | 85.3 13.8 | 78.0 11.0 | 81.4 12.8 |
| Serum total cholesterol (mmol/L) | 4.9 0.9 | 5.0 0.9 | 4.9 0.9 | 5.0 0.9 |
| Serum creatinine (μmol/L) | 81.3 14.1       | 84.9 17.7        | 80.0 17.7        | 48.9 12.7        |
| Serum glucose (mmol/L)   | 7.1 1.7          | 7.5 2.2          | 7.0 1.8          | 7.1 1.8          |
| Follow-up time (year)    | 17.4 3.9         | 16.3 5.2         | 17.9 3.3         | 16.9 4.8         |
| Current smoker           | 1915 (64.0%)     | 123 (66.1%)      | 328 (8.6%)       | 24 (11.0%)       |
| Current drinker          | 2264 (75.6%)     | 136 (73.1%)      | 783 (20.6%)      | 44 (20.1%)       |
| High serum cholesterol   | 161 (5.4%)       | 18 (9.7%)        | 281 (7.4%)       | 25 (11.4%)       |
| Low serum cholesterol    | 646 (21.6%)      | 33 (17.7%)       | 747 (19.6%)      | 32 (14.6%)       |
| Leanness (BMI<20)        | 598 (20.0%)      | 32 (17.2%)       | 766 (20.1%)      | 53 (24.2%)       |
| Obesity (BMI>25)         | 526 (17.6%)      | 49 (26.3%)       | 745 (19.6%)      | 67 (30.6%)       |
| Hypertension             | 533 (17.8%)      | 54 (29.0%)       | 397 (10.4%)      | 57 (26.0%)       |
| Hyperglycemia            | 464 (15.5%)      | 51 (27.4%)       | 617 (16.2%)      | 50 (22.8%)       |

* includes trace, +, ++ and more.

Hyperglycemia was defined as a blood sugar level of 7.7 mmol/L or greater when the time from the last meal before blood sampling was two hours or longer and/or 11.1 mmol/L or greater when the elapsed time between the last meal and sampling was less than two hours.

High serum cholesterol was defined as a serum cholesterol level of 6.2 mmol/L or greater. Low serum cholesterol was defined when a serum cholesterol level was less than 4.1 mmol/L.

The definition of hypertension was a systolic blood pressure of 160 mmHg or greater and/or a diastolic blood pressure of 95 mmHg or greater.

The serum creatinine level (μmol/L) was rated separately for men “low” (serum creatinine<97), “standard” (97-105), and “high”(106+) and women “low”(<71); “standard”(71-79); and “high”(80+).
Proteinuria and Cardiovascular Mortality

Table 3. Hazard ratios of proteinuria for all cause and cardiovascular mortality.

|                | All cause mortality |                                | Cardiovascular mortality |                                |
|----------------|---------------------|--------------------------------|--------------------------|--------------------------------|
|                | Age-adjusted        | Multivariate                   | Age-adjusted             | Multivariate                   |
|                | hazard ratio (95% CI)| hazard ratio (95% CI)          | hazard ratio (95% CI)    | hazard ratio (95% CI)          |
| negative       | 1.00 (reference)    | 1.00 (reference)               | 1.00 (reference)         | 1.00 (reference)               |
| trace          | 1.13 (0.77-1.65)    | 1.13 (0.77-1.65)               | 1.48 (0.80-2.73)         | 1.44 (0.78-2.67)               |
| +              | 0.72 (0.38-1.34)    | 0.67 (0.35-1.26)               | 0.46 (0.12-1.87)         | 0.35 (0.09-1.44)               |
| ++ and more    | 2.07 (0.86-4.98)    | 1.76 (0.72-4.29)               | 6.21 (2.29-16.80)        | 4.20 (1.50-11.72)              |
| p-value for trend | 0.1443              | 0.2083                         | 0.0062                   | 0.0467                         |
| trace,+,++,and more | 1.58 (1.20-2.08) | 1.22 (0.92-1.61)              | 2.17 (1.39-3.38)         | 1.49 (0.95-2.34)               |

|                | Male                |                                | Female                   |                                |
| negative       | 1.00 (reference)    | 1.00 (reference)               | 1.00 (reference)         | 1.00 (reference)               |
| trace          | 1.50 (0.98-2.30)    | 1.48 (0.96-2.28)               | 1.56 (0.73-3.34)         | 1.61 (0.75-3.47)               |
| +              | 1.97 (1.08-3.58)    | 1.91 (1.04-3.52)               | 3.42 (1.51-7.75)         | 3.08 (1.31-7.26)               |
| ++ and more    | 1.30 (0.42-4.05)    | 1.19 (0.38-3.74)               | 2.27 (0.56-9.19)         | 2.01 (0.48-8.31)               |
| p-value for trend | 0.0005              | 0.0016                         | 0.0002                   | 0.0016                         |
| trace,+,++,and more | 1.75 (1.29-2.38) | 1.74 (1.27-2.38)              | 2.41 (1.51-3.84)         | 2.21 (1.36-3.59)               |

Age, smoking, drinking, serum cholesterol, hyperglycemia, leanness, obesity, and hypertension were adjusted in multivariate analysis.
* regrouped
CI: confidence interval

Table 4. Stratified analysis by serum creatinine level for proteinuria for cardiovascular mortality.

| serum creatinine level (μmol/L) | n   | Proteinuria positive* (%) | Cardiovascular death (%) | Hazard ratio (95% CI) |
|----------------------------------|-----|---------------------------|--------------------------|-----------------------|
| Adjusted for age, smoking, drinking, serum cholesterol, hyperglycemia, leanness, obesity, and hypertension.
Proteinuria includes trace,+,++, and more. |

|                | Male (n=3180) |                                | Female (n=4023) |                                |
|----------------|---------------|--------------------------------|-----------------|--------------------------------|
| 106+           | 644           | 96 (14.9%)                    | 60 (9.3%)       | 1.07 (0.45 -2.57)              |
| 97-105          | 724           | 44 (6.1%)                     | 42 (5.8%)       | 4.07 (1.80 -9.20)              |
| -96             | 1812          | 46 (2.5%)                     | 9 (0.5%)        | 0.84 (0.36 -1.93)              |
| 80+             | 1661          | 44 (2.6%)                     | 104 (6.3%)      | 2.36 (1.33 -4.19)              |
| 71-79           | 1376          | 65 (4.7%)                     | 42 (3.1%)       | 2.41 (0.77 -7.54)              |
| -70             | 986           | 110 (11.2%)                   | 28 (2.8%)       | 1.03 (0.12 -9.17)              |
Our results indicated that proteinuria is related to an increased risk of death from cardiovascular disease among persons with no history of diabetes mellitus, hypertension, acute myocardial infarction, or stroke. Prospective data on proteinuria and mortality among the general population are limited. A number of prospective epidemiologic studies have reported that proteinuria or urinary albumin is a predictor of death for those with diabetes and hypertension. Most of the prospective studies on urinary protein or albumin and mortality were conducted in European countries and in the United States. The results of our study are unique because the study subjects were composed of a representative cohort of the Japanese population.

The hazard ratios for cardiovascular mortality increased with the level of proteinuria. The level of proteinuria was proportional to the risk of mortality. In this study, the positive sign of urinary protein is defined according to the urinary dipstick test result (as trace, +, ++ and more). Although without significance, the hazard ratios for cardiovascular mortality in subjects with "trace" proteinuria were higher than unity for both men and women. It is consistent with studies reporting that even lesser degrees of albuminuria predict cardiovascular events even after subjects with dipstick-positive (i.e., less than or equal to +) proteinuria had been excluded.

Our results showed that urinary protein, measured by dipstick methods, is an independent risk factor for cardiovascular death. In the most of studies, urinary protein was measured with a dipstick and the positive sign for proteinuria was defined when the test result was + or more, 300+mg/24h, 12 or >30mg/dL. Measuring urinary protein with a dipstick is a useful screening test because it is very simple and inexpensive. Finding the optimal cut-off point in the urinary dipstick test requires further consideration.

There are some limitations to be considered in this study. For example, potentially important confounding factors, such as postmenopausal status and waist and hip measurements were not obtained at the initial survey. Among subjects lost in follow-up, the proportion of subjects with proteinuria was higher than subjects selected for the analysis. The results of this study underestimated true relation between mortality and urine protein because it is presumable that subjects lost in follow-up have higher all cause and cardiovascular mortality. It means that the direction of bias produced by subjects lost in follow-up is toward null value. The observed hazard ratios are probably closer to the null than what it would be if the subjects lost in follow-up were absent.

Urinary protein was measured only once using an available urine sample so that it is possible that it may be misclassified in reading the results. It is also true that urinary protein is determined at the baseline before the survival or cause of death of the surveyed subjects becomes known through follow-up studies; and it is judged that any misclassification, if it occurs, is non-differential. If so, the effect of the risk factor that has been computed must be smaller than the real value and has no bearing on the conclusion of the present study, i.e., urinary protein is an independent risk factor of mortality from cardiovascular diseases.

Microalbuminuria correlates with cardiovascular autonomic dysfunction and insulin resistance in type 2 diabetic patients. In hypertensive subjects, the inflammatory injury in the kidney structures consequent to that of myocardial infarction causes a greater albumin leak. However, precise underlying pathophysiologic mechanisms of the association between proteinuria and unfavorable cardiovascular outcome among persons with no history of diabetes mellitus, hypertension, acute myocardial infarction, or stroke have not been totally given.

The results of the analysis that excluded subjects deceased or lost in the first three years of follow-up and the stratified analysis by serum creatinine level were different with men and women. For males, the risk of proteinuria for cardiovascular mortality was significantly higher than unity in the group with standard serum creatinine level. For female subjects, the risk of proteinuria was significantly higher than unity in the group with high creatinine level. It is reported that a possible difference in the mechanism or significance of urinary albumin excretion between both genders. Future studies on proteinuria should take factors related sex, menopausal status for example, into account.

In conclusion, urinary protein is an independent risk factor for cardiovascular death among the Japanese population especially in relation to their medical histories, blood pressure status and blood sugar level. Measuring urinary protein by the dipstick method is useful in locating persons with a high risk for cardiovascular mortality because it is simple and easy to conduct during a mass screening.

1. Morrisey NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: Associated risk factors. Diabetologia 1990; 33: 542-8.
2. Stiegler H, Standl E, Schulz K, Roth R, Lehmacier W. Morbidity, mortality, and albuminuria in type 2 diabetic patients: a three-year prospective study of a random cohort in general practice. Diabet Med 1992; 9: 646-53.
3. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16: 996-1003.
4. Bianchi S, Bigazzi R, Quinones Galvan A, Muscelli E, Baldari G, Pecorini L, et al. Insulin resistance in microalbuminuric hypertension. Sites and mechanisms. Hypertension 1995; 26: 789-95.
5. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, et al. Predictors of 10-year macrovascular and...
overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39: 1540-5.
6. Pontiroli AE, Pacchioni M, Camisasca R, Lattanzio R. Markers of insulin resistance are associated with cardiovascular morbidity and predict overall mortality in long-standing non-insulin-dependent diabetes mellitus. Acta Diabetol 1998; 35: 52-6.
7. Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, et al. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes 1998; 47: 1786-92.
8. Chen KT, Chen CJ, Fuh MM, Narayan KM. Causes of death and associated factors among patients with non-insulin-dependent diabetes mellitus in Taipei, Taiwan. Diabetes Res Clin Pract 1999; 43: 121-6.
9. Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Albuminuria and other risk factors for mortality in patients with non-insulin-dependent diabetes mellitus aged under 65 years: a population-based prospective 5-year study. Diabetes Res Clin Pract 1999; 43: 101-9.
10. Sievers ML, Bennett PH, Roumain J, Nelson RG. Effect of hypertension on mortality in Pima Indians. Circulation 1999; 100: 33-40.
11. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093-100.
12. Casiglia E, Zanette G, Mazza A, Donadon V, Donada C, Pizziol A, et al. Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. Eur J Epidemiol 2000; 16: 677-84.
13. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
14. Roest M, Banga JD, Janssen WM, Grobbee DE, de Jong PE, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103: 3057-61.
15. Pontremoli R, Viazzese F, Martinelli C, Raveri M, Nicolla C, Berruti V, et al. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant 1999; 14: 360-5.
16. Grimm RH Jr, Svedens KH, Kasiskie B, Keane WF, Wahi MM. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl 1997; 63: S10-S14.
17. Segura J, Campo C, Rulope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int Suppl 2004; S45-S49.
18. Tsoufi C, Dimitriadis K, Antoniadis D, Stefanadis C, Kalikazaros I. Inter-relationships of microalbuminuria with the other surrogate of the atherosclerotic cardiovascular dis-ease in hypertensive subjects. Am J Hypertens. 2004; 17: 470-6.
19. Berton G, Cordiano R, Palmieri R, Cucchinri F, De Toni R, Palatini P. Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality. Eur Heart J 2001; 22: 1466-75.
20. Casiglia E, Pauletto P, Mazza A, Ginocchio G, Di Menza G, Pavan L, et al. Impaired glucose tolerance and its co-variates among 2079 non-diabetic elderly subjects. Ten-year mortality and morbidity in the CASTEL study. Cardiovascular STudy in the ELderly. Acta Diabetol 1996; 33: 284-90.
21. Casiglia E, Spolaoare P, Ginocchio G, Colangelo G, Di Menza G, Marchiori M, et al. Predictors of mortality in very old subjects aged 80 years or over. Eur J Epidemiol 1993; 9: 577-86.
22. Nakanishi N, Takatorige T, Fukuda H, Shirai K, Li W, Okamoto M, et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 2004; 64: 59-70.
23. Howard BV, Lee ET, Cowan LD, Devereux RB, Galloway JM, Go OT, et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 1999; 99: 2389-95.
24. Ministry of Health and Welfare. National Survey on Circulatory Disorders 1980. Tokyo: Japan Heart Foundation, 1982.
25. Hayakawa T, Okayama A, Ueshima H, Kita Y, Choudhury SR, Tamaki J. Prevalence of impaired activities of daily living and the impact of stroke and lower limb fracture in elderly persons in Japan. CVD prevention 2000; 3: 187-194.
26. Sakata K, Hashimoto T, Ueshima H, Okayama A. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. Eur J Epidemiol 2001; 17: 461-8.
27. Kanai S, Sekiguchi M, Nomoto S, Cleatine and Cleatine. In: Kanai S, eds. Kanai’s Manual of Clinical Laboratory Medicine, 31th ed. Kanahara, Tokyo. (in Japanese)
28. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-85.
29. Takahashi N, Anan F, Nakagawa M, Yufu K, Ooie T, Nawata T, et al. Microalbuminuria, cardiovascular autonomic dysfunction, and insulin resistance in patients with type 2 diabetes mellitus. Metabolism 2004; 53: 1359-64.
30. Gosling P, Hughes EA, Reynolds TM, Fox JP. Microalbuminuria is an early response following acute myocardial infarction. Eur Heart J 1991; 12: 508-13.
31. Verhave JC, Hillege HL, Burgerhof JG, Nasis G, de Zeeuw D, de Jong PE for the PREVEND Study Group. Cardiovascular risk factors are differently associated with uri-
Tanihara S, et al.

Tanihara S, et al. Nary albumin excretion in men and women. J Am Soc Nephrol 2003; 14: 1330-5.

List of the NIPPON DATA80 Research group

NIPPON DATA80: "National Integrated Projects for Prospective Observation of Non-communicable Diseases And its Trends in the Aged"

Chairman: Hirotugu Ueshima (Department of Health Science, Shiga University of Medical Science, Otsu, Shiga)

Consultant: Osamu Iimura (Hokkaido JR Sapporo Hospital, Sapporo, Hokkaido), Teruo Omae (National Cardiovascular Center, Suita, Osaka), Kazuo Ueda (School of Health Science, Kyushu University, Fukuoka, Fukuoka), Hiroshi Yanagawa (Saitama Prefectural University, Koshigaya, Saitama)

Research Member: Akira Okayama (Preventive Cardiology National Cardiovascular Disease Center, Suita, Osaka), Kazunori Kodama, Fumiyoshi Kasagi (Radiation Effects Research Foundation, Hiroshima, Hiroshima), Tomonori Okamura, Yoshikuni Kita (Department of Health Science, Shiga University of Medical Science, Otsu, Shiga), Shigeyuki Saito (Internal Medicine ʲ, Cardiology and Nephrology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido), Kiyomi Sakata (Department of Hygiene and Preventive Medicine, Iwate Medical University School of Medicine, Morioka, Iwate), Takehito Hayakawa, Shinichi Tanihara (Department of Public Health, School of Medicine, Shimane University, Izumo, Shimane), Yosikazu Nakamura (Department of Public Health, Jichi Medical School, Minami Kawachi, Tochigi), Hiroshi Horibe (Keisen Clinic, Akashi, Hyogo), Masumi Minowa (Department of Epidemiology, National Institute of Public Health, Wako, Saitama)

Research Associate Member: Toshihiro Takeuchi, Mitsuru Hasebe, Fumisugu Kusano and members of 300 Public Health Centers in Japan, Katsuhiko Kawaminami (Department of Public Health Policy, National Institute of Public Health, Wako, Saitama), Sohel R. Choudhury, (Department of Community Medicine, School of Medical Sciences University Sains Malaysia), Yutaka Kiyohara (Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Fukuoka), Minoru Iida (Kansai University of Welfare Sciences, Osaka), Tsutomu Hashimoto (Wakayama Red Cross Blood Center, Wakayama, Wakayama), Atsushi Terao (Hikone Public Health Center, Hikone, Shiga), Koryo Sawai (The Japanese Association for Cerebro-cardiovascular Disease Control, Tokyo, Tokyo), Shigeo Shibata (Clinical Nutrition, Kagawa Nutrition University, Saitama)